SANA Sana Biotechnology Inc.

19.92
-0.6  -3%
Previous Close 20.52
Open 20.43
52 Week Low 16.28
52 Week High 44.6
Market Cap $3,738,498,908
Shares 187,675,648
Float 85,905,297
Enterprise Value $3,332,724,080
Volume 318,480
Av. Daily Volume 421,476
Stock charts supplied by TradingView

Latest News

  1. New Board Members Will Help Advance ‘Gene Writing' Platform and Mission to Cure Disease by Writing in the Code of Life

    Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the company's Board of Directors. This announcement represents the latest key development for Tessera, following the March appointments of David Davidson, M.D. as Chief Medical and Development Officer, Hari Pujar, Ph.D. as Chief Operating Officer, and Lin Guey, Ph.D. as Senior Vice President of Rare Diseases Program Strategy and Operations, and a $230 million Series B fundraising round in January.

    "Elliott and Mary bring phenomenal leadership, experience, and creativity…

    New Board Members Will Help Advance ‘Gene Writing' Platform and Mission to Cure Disease by Writing in the Code of Life

    Tessera Therapeutics, a biotech company pioneering Gene Writing, announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the company's Board of Directors. This announcement represents the latest key development for Tessera, following the March appointments of David Davidson, M.D. as Chief Medical and Development Officer, Hari Pujar, Ph.D. as Chief Operating Officer, and Lin Guey, Ph.D. as Senior Vice President of Rare Diseases Program Strategy and Operations, and a $230 million Series B fundraising round in January.

    "Elliott and Mary bring phenomenal leadership, experience, and creativity to Tessera's Board of Directors," said Geoffrey von Maltzahn, Ph.D., CEO and Co-Founder of Tessera. "Elliott has overseen more than a dozen new medications on their way to market, and Mary has guided major strategic, fundraising, and partnership efforts. Together, they offer decades of experience that will help us rapidly grow Tessera and to fulfill our mission of curing diseases by writing in the code of life."

    "The next frontier in medicine will be therapeutics that cure and provide enduring protection against disease. I am excited to welcome Elliott and Mary to the team at Tessera and look forward to working closely with them as we advance Tessera's Gene Writing platform and pioneer the future of genetic medicine," said Noubar Afeyan, Ph.D., Co-founder and Chairman of the Board, Tessera and CEO of Flagship Pioneering.

    Dr. Sigal brings decades of clinical experience in drug discovery, drug development, and corporate strategy to Tessera's Board of Directors. He currently serves as a senior advisor to the healthcare team of New Enterprise Associates and is a member of the Board of Directors for Adaptimmune Therapeutics, Surface Oncology, Vir Therapeutics, and Affinia. He co-chairs the Scientific Advisory Board for Amgen and is a member of the Scientific Steering Committee for the Sean Parker Institute for Cancer Immunology. He previously served on the Board of Directors for the gene therapy company, Spark Therapeutics. Dr. Sigal is a former Executive Vice President and Director of Bristol-Myers Squibb, and served as the company's Chief Scientific Officer and President of R&D from 2004 until 2013. Under his leadership, fourteen new medicines came to market in multiple therapeutic areas including virology, oncology, immunology, psychiatry, metabolic diseases and cardiovascular disease. During his tenure, Dr. Sigal was named the best R&D chief in the pharmaceutical industry by Scrip Intelligence. Dr. Sigal received his M.D. from the University of Chicago and trained in Internal Medicine and Pulmonary Medicine at UCSF. Prior to medical school, he received his B.S., M.S., and Ph.D. in Industrial Engineering from Purdue University.

    "Tessera's Gene Writing technology represents a major breakthrough in the field with potential to fundamentally change the future of medicine across many therapeutic areas," said Dr. Elliott Sigal. "I am honored to join the Board and look forward to helping guide the company through continued growth and innovation."

    Dr. Rozenman brings more than 15 years of scientific expertise, company building, and transactions leadership in the biotech industry to Tessera's Board of Directors. She serves as the CFO and CBO of insitro, leading strategic and operational finance and accounting strategy, business development, investor relations, corporate communications, as well as project and portfolio management. Prior to insitro, Dr. Rozenman served as the Senior Vice President of Corporate Development and Strategy at Aimmune Therapeutics, where she oversaw business development and partnerships with companies including Regeneron/Sanofi and Nestle Health Science and supported the company's strategic finance and investor relations efforts. Across her time at both insitro and Aimmune, Dr. Rozenman has raised more than $1 billion in capital through a range of public and private transactions, including leadership of Aimmune's IPO in 2015. She received her Ph.D. in Organic Chemistry and Chemical Biology from Harvard University and her B.A. in Biochemistry and Russian Literature from Columbia University.

    "Tessera is pioneering Gene Writing at a pivotal moment for drug discovery, as we rapidly expand our understanding of the genetic drivers of disease. Tessera's work to write into the genome may open opportunities to cure and prevent a broad range of diseases. I am thrilled to join the Board during such an exciting time in the company's growth and look forward to partnering with Geoff and the world class Tessera team," said Dr. Mary Rozenman.

    For more information on Tessera, including how Gene Writing works, partnership opportunities, and job openings, visit www.tesseratherapeutics.com.

    About Tessera Therapeutics

    Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing holds the potential to become a new category in genetic medicine, building upon recent breakthroughs in gene therapy and gene editing while eliminating important limitations in their reach, utilization, and efficacy. Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability.

    About Flagship Pioneering

    Flagship Pioneering conceives, creates, resources, and develops first-in-category life science platform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $90 billion in aggregate value. To date, Flagship has deployed over $2.4 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ:AXLA), Codiak BioSciences (NASDAQ:CDAK) Denali Therapeutics (NASDAQ:DNLI), Evelo Biosciences (NASDAQ:EVLO), Foghorn Therapeutics (NASDAQ:FHTX), Indigo Ag, Kaleido Biosciences (NASDAQ:KLDO), Moderna (NASDAQ:MRNA), Rubius Therapeutics (NASDAQ:RUBY), Sana Biotechnology (NASDAQ:SANA), Seres Therapeutics (NASDAQ:MCRB), and Sigilon Therapeutics (NASDAQ:SGTX).

    View Full Article Hide Full Article
  2. SEATTLE , June 14, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during two plenary sessions at the International Society for Stem Cell Research 2021 Virtual Annual Meeting, to be held Monday, June 21 through Saturday, June 26.

    Chuck Murry, M.D., Ph.D., Sana's Head of Cardiometabolic Cell Therapy, will be presenting "Genome Editing to Eliminate Engraftment Arrhythmia during Heart Regeneration" during the conference's first plenary session, the Presidential Symposium titled ‘What's in a Germ Layer?' The session will begin on Monday, June 21 at 9:30 a.m. ET and will end at 11:45 a.m. ET.

    Sonja Schrepfer…

    SEATTLE , June 14, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on creating and delivering engineered cells as medicines, today announced that data will be presented during two plenary sessions at the International Society for Stem Cell Research 2021 Virtual Annual Meeting, to be held Monday, June 21 through Saturday, June 26.

    Chuck Murry, M.D., Ph.D., Sana's Head of Cardiometabolic Cell Therapy, will be presenting "Genome Editing to Eliminate Engraftment Arrhythmia during Heart Regeneration" during the conference's first plenary session, the Presidential Symposium titled ‘What's in a Germ Layer?' The session will begin on Monday, June 21 at 9:30 a.m. ET and will end at 11:45 a.m. ET.

    Sonja Schrepfer, M.D., Ph.D., Sana's Head of Hypoimmune Platform, will be speaking during the sixth plenary session on Cellular Therapy and Tissue Engineering, highlighting the Clinical Applications conference theme. She will present "Protecting Transplanted Stem Cells from Immune Rejection." The plenary session will begin on Saturday, June 26 at 9:30 a.m. ET and will end at 11:00 a.m. ET.

    Both presentations will be rebroadcast at 9:30 p.m. ET on the day of their presentation and will be available to ISSCR registrants for on-demand viewing through July 31, 2021.

    About Sana Biotechnology

    Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are more than 300 people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, and South San Francisco. For more information about Sana Biotechnology, please visit https://sana.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements about Sana Biotechnology, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws, including those related to the Company's vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its pre-clinical, clinical and regulatory development plans and timing expectations; expectations for the presentation or publication of data, including in medical or scientific journals; and the content of the Company's presentations at the International Society for Stem Cell Research 2021 Virtual Annual Meeting. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company's strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company's current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's SEC reports, including but not limited to its Annual Report on Form 10-K dated March 24, 2021 and Quarterly Report on Form 10-Q dated May 5, 2021. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

    All product and company names herein may be trademarks of their registered owners.

    Investor Relations:

    Nicole Keith

    Media:

    Morgan Warners, Finsbury Glover Hering



    Primary Logo

    View Full Article Hide Full Article
  3. CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health and sustainability companies. Flagship re-opened Fund VII in April 2021 to current Limited Partners and a select group of new investors, raising an additional $2.23 billion for a total capital pool of $3.37 billion. This brings together for the first time its origination and growth strategies under one investment vehicle with a long-term focus on the creation, development, and growth of its first-in-category bioplatform companies.

    CAMBRIDGE, Mass., June 14, 2021 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced a significant expansion of its capital base to support founding and growing its next generation of human health and sustainability companies. Flagship re-opened Fund VII in April 2021 to current Limited Partners and a select group of new investors, raising an additional $2.23 billion for a total capital pool of $3.37 billion. This brings together for the first time its origination and growth strategies under one investment vehicle with a long-term focus on the creation, development, and growth of its first-in-category bioplatform companies.

    "At Flagship Pioneering, we are re-imagining how to prevent and treat disease, feed a growing population, and sustain our planet. We do this by harnessing chemistry, biology, and machine learning/AI to build cohesive, integrated platforms, each with the potential for multiple transformative products," said Noubar Afeyan, Ph.D., Founder and Chief Executive Officer of Flagship Pioneering. "There is no better example of the power of bioplatform companies than Flagship-founded Moderna, which was able to rapidly shift its focus in 2020 to develop, test, and deploy its COVID-19 vaccine in record time."

    Dr. Afeyan continued, "In the last year alone, breakthroughs at Rubius Therapeutics, Denali Therapeutics, Seres Therapeutics, and others demonstrated the exponential impact bioplatforms can have on health. Biotechnology is at the leading edge of technological progress, challenging us to think beyond incremental advances and take big leaps – and Flagship Pioneering is focused on actively leaping to the scientific spaces ripe for disruption."

    Financial Update

    After Fund VII's close, Flagship is now operating with an aggregate capital pool of $6.7 billion, with $14.1 billion assets under management. Over the past four quarters, Flagship deployed $370 million in capital to its companies, combined with more than $4.4 billion from other capital providers, for a total of $4.8 billion in new capital fueling Flagship companies.

    "We are grateful to our longstanding Limited Partners and our new investors for their support as we pioneer life science solutions to tackle the world's most urgent issues," said Stephen Berenson, Managing Partner, Flagship Pioneering. "This expanded capital pool will enable us to support first-in-category platform companies, spanning human therapeutics, agriculture, and nutrition, as well as our soon-to-be-launched Preemptive Medicine and Health Security Initiative, and the development of a robust pipeline of clinical assets through our Pioneering Medicines Division."

    Driving Ground-breaking Multi-Product Bioplatforms                                      

    Flagship Pioneering is dedicated to exploring and innovating in uncharted spaces, as well as founding, launching, and advancing new companies to develop and commercialize these innovations.

    "The biological century is an era of new possibility. Today, the opportunity to harness biology for the benefit of humanity and the world is unprecedented," said Doug Cole, M.D., Managing Partner, Flagship Pioneering. "At Flagship, we challenge ourselves daily to discover what is not yet visible, invent what has previously not been possible, and imagine and realize new ways to treat, cure, diagnose, and prevent diseases."

    Flagship's team of entrepreneurial scientists, executives, and operations experts, as well as its companies, achieved important milestones in the last year, as follows:

    • Unveiled Generate Biomedicines, Invaio Sciences, Inzen Therapeutics, Laronde, and Valo Health
    • Raised $1.8 billion in private investments for early growth-stage companies: Cellarity, Inari Agriculture, Indigo Ag, Invaio Sciences, Omega Therapeutics, Repertoire Immune Medicines, Ring Therapeutics, Senda Biosciences, Tessera Therapeutics, and Valo Health
    • Completed Initial Public Offerings at Codiak Biosciences (NASDAQ:CDAK), Foghorn Therapeutics (NASDAQ:FHTX), Sana Biotechnology (NASDAQ:SANA), and Sigilon Therapeutics (NASDAQ:SGTX)
    • Raised follow-on public market capital in Axcella (NASDAQ:AXLA), Codiak Biosciences (NASDAQ:CDAK), Evelo (NASDAQ:EVLO), Kaleido (NASDAQ:KLDO), Moderna (NASDAQ:MRNA), Rubius (NASDAQ:RUBY), and Seres (NASDAQ:MCRB)
    • Conducted more than 60 new explorations, the first step of our company origination process
    • Filed more than 300 patent applications from Flagship Labs
    • Flagship ecosystem companies have 53 clinical programs and 150 pre-clinical programs currently underway

    Assembling a World-Class Team

    Flagship is committed to bringing on the highest caliber industry executives with track records of exceptional performance, as evidenced in the company's new hires over the past year. These have included the recent additions of Christopher P. Austin, M.D., as CEO-Partner, Ara Darzi, M.D., as Chair, Preemptive Medicine and Health Security Initiative, Michael T. Nally, as CEO-Partner and CEO of Generate Biomedicines, and Louisa Salter-Cid, Ph.D., as Chief Scientific Officer for Pioneering Medicines. In addition, Flagship has hired a number of world class executives, scientists, and operations leaders to roles across the company and its ecosystem of companies. 

    Introducing Preemptive Medicine and Health Security, a New, More Comprehensive Approach to Health Security

    Flagship is actively building a division tasked with pioneering a new field that aims to protect, maintain, or improve people's health before they get sick by proactively intervening in those who are seemingly healthy but at risk. It will encompass interventions that protect health from external threats (health security) as well as to prevent or delay the onset of disease (preemptive health) to better prepare for the next infectious disease threats, and to pursue bolder treatments for existing pandemic diseases such as obesity, cancer, and neurodegeneration. Learn more about Flagship's perspective in this recent whitepaper, "Health Security and Beyond: A New Paradigm for a Post-Pandemic World."

    "The pandemic has laid bare the critical nature of health, not only to individuals, but to economies and societies," said Ara Darzi, M.D., Chair of Flagship's Preemptive Medicine and Health Security Initiative. "Flagship is pioneering a new field that aims to protect, maintain, and improve people's health by providing security against threats for everyone, and preventing or postponing the onset of disease for 'seemingly healthy' people, before they experience any recognisable symptoms at all."

    Building the Pioneering Medicines Division

    Flagship launched its Pioneering Medicines Division earlier this year to harness the power of Flagship's scientific and development innovation to create and advance novel therapeutic medicines that benefit more patients sooner. Given the broad applicability of many Flagship platforms, Pioneering Medicines is focused on expanding the reach of these scientific innovations by creating medicines in disease areas where the companies are not yet focused and working across platforms in unprecedented ways.

    "Pioneering Medicines is focused on innovative approaches to achieving greater impact for patients at faster speeds," said Paul Biondi, Executive Partner, Flagship Pioneering and President of Pioneering Medicines. "We are leveraging the innovative scientific platforms and technologies within Flagship Pioneering's ecosystem of companies to conceive and develop a unique portfolio of life-changing treatments for patients."

    About Flagship Pioneering

    Flagship Pioneering conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $90 billion in aggregate value. To date, Flagship has deployed over $2.4 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Denali Therapeutics (NASDAQ:DNLI), Indigo Ag, Moderna (NASDAQ:MRNA), Rubius Therapeutics (NASDAQ:RUBY), Sana Biotechnology (NASDAQ:SANA), Seres Therapeutics (NASDAQ:MCRB), and Valo Health.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/flagship-pioneering-closes-3-4-billion-capital-pool-to-drive-continued-breakthrough-innovations-in-human-health-and-sustainability-301311419.html

    SOURCE Flagship Pioneering

    View Full Article Hide Full Article
  4. SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference at 12:00 p.m. PT on Wednesday, June 9, 2021. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

    The webcast will be accessible on the Investor Relations page of Sana's website at www.Sana.com. A replay of the presentation will be available at the same location for 30 days following the conference.

    About Sana Biotechnology
    Sana Biotechnology, Inc. is focused on creating and delivering engineered cells…

    SEATTLE, June 02, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast its presentation at the Goldman Sachs 42nd Annual Global Healthcare Conference at 12:00 p.m. PT on Wednesday, June 9, 2021. The presentation will feature a business overview and update by Steve Harr, Sana's President and Chief Executive Officer.

    The webcast will be accessible on the Investor Relations page of Sana's website at www.Sana.com. A replay of the presentation will be available at the same location for 30 days following the conference.

    About Sana Biotechnology

    Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are more than 280 people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, Cambridge, and South San Francisco. For more information about Sana Biotechnology, please visit https://sana.com/.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements about Sana Biotechnology, Inc. (the "Company," "we," "us," or "our") within the meaning of the federal securities laws, including those related to the Company's vision, progress, and business plans; expectations for its development programs, product candidates and technology platforms, including its pre-clinical and clinical and regulatory development plans and timing expectations; Sana's participation in the Goldman Sachs 42nd Annual Global Healthcare Conference; and the subject matter of Sana's presentation at that conference. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company's strategy, expectations, cash runway and future financial condition, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "aim," "anticipate," "assume," "believe," "contemplate," "continue," "could," "design," "due," "estimate," "expect," "goal," "intend," "may," "objective," "plan," "positioned," "potential," "predict," "seek," "should," "target," "will," "would" and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company's current and future research and development programs, preclinical and clinical trials, as well as the economic, market and social disruptions due to the ongoing COVID-19 public health crisis. For a detailed discussion of the risk factors that could affect the Company's actual results, please refer to the risk factors identified in the Company's SEC reports, including but not limited to its Annual Report on Form 10-K dated March 24, 2021 and Quarterly Report on Form 10-Q dated May 5, 2021. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.

    Investor Relations:

    Nicole Keith

    Media:

    Morgan Warners, Finsbury Glover Hering



    Primary Logo

    View Full Article Hide Full Article
  5. CAMBRIDGE, Mass., May 25, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet's interdependent natural systems to solve pressing agriculture, nutrition and environmental challenges, today announced the closing of a Series C financing round totaling $88.9 million. Joining founder and principal backer Flagship Pioneering is Stage 1 Ventures, Bluwave Capital, Alexandria Venture Investments, and others. With this financing, Invaio has raised more than $142 million since its founding in 2018.

    "Our ambition is to build the most impactful and valuable crop health company on the planet," said Ignacio Martinez, Co-Founder and CEO of Invaio. "The world is changing quickly, and food production practices must adapt to keep pace with evolving consumer demands, changing environmental conditions and increased stress on ecological resources."

    "This commitment by new and existing investors enables Invaio to accelerate the expansion of our integrated technology platforms that will solve performance and delivery challenges facing the agriculture industry. Our approach to reducing the use of fertilizers and chemicals will revolutionize the industry and guide the production of food to biological practices in less than a decade," explained Martinez.

    Teeming with pioneering technologies, extraordinary talent, and an insurgent mindset, Invaio Sciences has focused research and development in large addressable perennial, row crop and vegetable marketplaces. With this most recent financing, Invaio will continue to delve deep into diverse areas of discovery including tree nutritional health, insect management, vector and disease control, transformative herbicides and fungicides replacements, advanced seed technologies, carbon cycling, and more.

    "This is an exciting time to be in agricultural science. Within the next decade, a new playbook for producing food will evolve and take root, and Invaio is at the forefront of this discovery, actively contributing to developing the model for agricultural production of the future," said Gerardo Ramos, Chief Science Officer, Invaio Sciences. "At Invaio, we take a systems approach: controlling the disease with minimal environmental impact by reducing the use of pesticides by more than 90 percent and increasing carbon capture while improving the health of the system as a whole. This is just the beginning."

    Already addressing some of the biggest concerns plaguing crop health throughout the planet, Invaio Sciences is gaining a foothold within perennial production. Resources from the Series C capital raise will immediately be used to roll out solutions for problems including HLB in the citrus industry, Xylella in Olive production, and to institute more refined practices in managing vineyards and orchards. Invaio is also advancing a new carbon offering for perennial producers and is working with the USDA to bolster the vitality of beehives through ensuring pollinator health and the longevity of flowering real food trees in the future.

    "Invaio is transitioning from an R&D-focused organization to a fully commercial enterprise," commented Peleg Chevion, President and Chief Commercial Officer of Invaio. "We're building an economically attractive approach to institute sustainable agriculture at scale for diverse growers around the world."

    Chevion continued, "We are deeply committed to delivering the right solutions for producers now, as well as taking a generational view of their operations and the entire value chain. Our use of precision delivery offers a cleaner, safer and more mindful approach to manage the need for healthier crops and more nutritious and efficient food production in the future."

    About Invaio Sciences:

    Invaio Sciences is a multi-platform technology company that unlocks the potential of the planet's interdependent systems to address pressing agricultural, nutritional, and environmental challenges. Founded by Flagship Pioneering in 2018, Invaio leverages discoveries from diverse fields including human therapeutics, agriculture, environmental science, and advanced manufacturing. The company's deep understanding of the physiology of insects, plants and trees, together with its novel integrated solutions approach, promises to refine agricultural practices and reduce the need for pesticides globally. Invaio Sciences is dedicated to developing solutions that are mindful of beneficial insects, bad for pests, and safer for us all.  For more information, please visit www.invaio.com

    About Flagship Pioneering:

    Flagship Pioneering conceives, creates, resources, and develops first-in-category life science platform companies to transform human health and sustainability. Since its launch in 2000, the firm has, through its Flagship Labs unit, applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures, resulting in over $80 billion in aggregate value. To date, Flagship has deployed over $2.3 billion in capital toward the founding and growth of its pioneering companies alongside more than $19 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 41 transformative companies, including Axcella Health (NASDAQ: AXLA), Codiak BioSciences (NASDAQ: CDAK) Denali Therapeutics (NASDAQ: DNLI), Evelo Biosciences (NASDAQ: EVLO), Foghorn Therapeutics (NASDAQ: FHTX), Indigo Ag, Inari Agriculture, Kaleido Biosciences (NASDAQ: KLDO), Moderna (NASDAQ: MRNA), Rubius Therapeutics (NASDAQ: RUBY), Sana Biotechnology (NASDAQ: SANA), Seres Therapeutics (NASDAQ: MCRB), and Sigilon Therapeutics (NASDAQ:SGTX).

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/invaio-sciences-raises-88-9-million-to-accelerate-the-transition-to-biological-agriculture-301298364.html

    SOURCE Invaio Sciences

    View Full Article Hide Full Article
View All Sana Biotechnology Inc. News